# US 2024/0189317 A1 · Antiviral compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189317 A1
- Document ID: US20240189317A1
- Status: Published application
- Kind: A1
- Application number: 18/281,942
- Filed: 2022-03-15
- Published: 2024-06-13
- Earliest claimed: 2021-03-16
- Assignees: AI Therapeutics, Inc.
- Applicants: AI Therapeutics, Inc.
- Inventors: Peter R. Young; Sean Landrette; Carlo Spirli; Keith Fandrick; Murat Gunel
- Web page: https://patentgrep.com/patent/US20240189317A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and related methods of using a PIKfyve inhibitor, such as apilimod, in combination with a serine protease inhibitor, for treating or preventing viral disease.

## Claims

### Claim 1

A pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, and a serine protease inhibitor.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the apilimod is in the form of a free base.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the apilimod is in the form of a salt and the pharmaceutically acceptable salt is a monosalt selected from the group consisting of chloride, fumarate, glycolate, D or L-lactate, maleate, malonate, mesylate, 1-hydroxy-2-naphthoate, phosphate, succinate, and L-tartrate.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the apilimod is in the form of a salt and the pharmaceutically acceptable salt is a disalt selected from the group consisting of mesylate, chloride, and bromide.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the apilimod is in the form of a dimesylate salt.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the serine protease inhibitor is selected from the group consisting of actinonin, amiloride, apixaban, aprotinin, argatroban, aspartame, atropine, batimastat, betrixaban, bromhexine, bupivacaine, camostat, cefixime, creatinine, dabigatran, dansyl-D-pheylalanine, darapladib, darexaban, dizocilpine, doxorubicin, doxycycline, ecopladib, edoxaban, efipladib, epichlortetracycline, epidemeclocycline, eribaxaban, gabexate, ginsenoside, giripladib, ilomastat, letaxaban, leupeptin, luteolin, marimastat, nafamostat, neostigmine, noradrenaline, otamixaban, phosphoramidon, prinomastat, rivaroxaban, sepimostat, sivelestat, suramin, tanomastat, thiorphan, tranexamic acid, trocade, tropicamide, varespladib, variabilin, and ximelagatran.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the serine protease inhibitor is selected from the group consisting of aprotinin, bromhexine, camostat, gabexate, nafamostat, otamixaban, and spimostat.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the serine protease inhibitor is an inhibitor of transmembrane protease, serine 2 (TMPRSS2).

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the TMPRSS2 inhibitor is selected from the group consisting of aprotinin, bromhexine, camostat, marimastat, nafamostat, phosphoramidon, sepimostat, and tannic acid.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the serine protease inhibitor is camostat or nafamostat.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is in the form of an oral dosage form or an intravenous dosage form.

### Claim 12

A method for treating or preventing viral disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, and a serine protease inhibitor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the apilimod is in the form of a free base.

### Claim 14 (depends on 12)

The method of claim 12, wherein the apilimod is in the form of a salt and the pharmaceutically acceptable salt is a monosalt selected from the group consisting of chloride, fumarate, glycolate, D or L-lactate, maleate, malonate, mesylate, 1-hydroxy-2-naphthoate, phosphate, succinate, and L-tartrate.

### Claim 15 (depends on 12)

The method of claim 12, wherein the apilimod is in the form of a salt and the pharmaceutically acceptable salt is a disalt selected from the group consisting of mesylate, chloride, and bromide.
